24/7 Wall St. on MSN19h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Option Trade Could Return More Than $1,300 On A Wobbly Eli Lilly
August and is down 20% in the last three months. If Eli Lilly continues to move lower, a bear put spread would be the best ...
Eli Lilly's (NYSE:LLY) Dividend Will Be Increased To $1.50
The board of Eli Lilly and Company ( NYSE:LLY ) has announced that it will be paying its dividend of $1.50 on the ...
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Josh Gottheimer
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...
Eli Lilly (NYSE:LLY) shareholders have earned a 44% CAGR over the last five years
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive ...
Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade
Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
Has Eli Lilly Stock Peaked?
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.
Rep. Josh Gottheimer Sells Eli Lilly and Company (NYSE:LLY) Stock
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...